Dipeptidylpeptidase-4 inhibitors (Gliptins)
Acute pancreatitis associated with gliptins has been reported. Inform patients of the symptoms of acute pancreatitis. If pancreatitis is suspected, the DPP-4 inhibitor should be discontinued.
• Only continue DPP-4 inhibitor therapy if the person has had a beneficial metabolic response (a reduction of at least 0.5 percentage points in HbA1c in 6 months) –as per NICE CG87.
• Monotherapy: Saxagliptin, Sitagliptin and Linagliptin – only if metformin contra-indicated or not tolerated. Alogliptin is not licensed for monotherapy.
• See individual SPCs for details of dosage in renal impairment.
GMMMG IPNTS: DPP-4 inhibitors (‘The Gliptins’) for the treatment of type 2 diabetes mellitus. Feb 2014